Treatment of familial male precocious puberty with spironolactone and testolactone

L. Laue, D. Kenigsberg, O. H. Pescovitz, K. D. Hench, K. M. Barnes, Donald (Lynn) Loriaux, G. B. Cutler

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Because the pubertal growth spurt in boys appears to be mediated by both androgens and estrogens, we hypothesized that blockade of both androgen action and estrogen synthesis would normalize the growth of boys with familial male precocious puberty. To test this hypothesis, we studied nine boys (age range, 3.3 to 7.7 years) during treatment with an antiandrogen (spironolactone) or an inhibitor of androgen-to-estrogen conversion (testolactone), followed by treatment with both agents. After six months of observation without treatment, the first four boys received spironolactone for six months, followed by spironolactone and testolactone. The next five boys received testolactone for six moths, followed by spironolactone and testolactone. Neither spironolactone nor testolactone, given alone, was satisfactorily as a treatment for this condition. However, a combination of spironolactone and testolactone, given for at least six months, restored both the growth rate and the rate of bone maturation to normal prepubertal levels and controlled acne, spontaneous erections, and aggressive behavior. The combined therapy was associated with a significantly lower growth rate than testolactone alone (P <0.05) and a significantly lower rate of bone maturation than spironolactone alone (P <0.05). No important adverse effects were observed during combined treatment. Six of the nine boys continued to receive the combined therapy for an additional 12 months and maintained normal prepubertal rates of growth and bone maturation. The mean predicted height (± SEM) increased progressively during the combined treatment although the difference between the pretreatment and post-treatment protections was not significant (169.5 ± 2.8 at the end of treatment vs. 166.2 ± 4.5 cm before treatment; P = 0.29). We conclude that blockade of both androgen action estrogen synthesis with the combination of spironolactone and testolactone is an effective short-term treatment for familial male precocious puberty. Further study will be required, however, to assess the long-term outcome in boys who receive this treatment.

Original languageEnglish (US)
Pages (from-to)496-502
Number of pages7
JournalNew England Journal of Medicine
Volume320
Issue number8
StatePublished - 1989
Externally publishedYes

Fingerprint

Testolactone
Spironolactone
Androgens
Therapeutics
Estrogens
Growth
Sexual precocity
Bone and Bones
Androgen Antagonists

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Laue, L., Kenigsberg, D., Pescovitz, O. H., Hench, K. D., Barnes, K. M., Loriaux, D. L., & Cutler, G. B. (1989). Treatment of familial male precocious puberty with spironolactone and testolactone. New England Journal of Medicine, 320(8), 496-502.

Treatment of familial male precocious puberty with spironolactone and testolactone. / Laue, L.; Kenigsberg, D.; Pescovitz, O. H.; Hench, K. D.; Barnes, K. M.; Loriaux, Donald (Lynn); Cutler, G. B.

In: New England Journal of Medicine, Vol. 320, No. 8, 1989, p. 496-502.

Research output: Contribution to journalArticle

Laue, L, Kenigsberg, D, Pescovitz, OH, Hench, KD, Barnes, KM, Loriaux, DL & Cutler, GB 1989, 'Treatment of familial male precocious puberty with spironolactone and testolactone', New England Journal of Medicine, vol. 320, no. 8, pp. 496-502.
Laue L, Kenigsberg D, Pescovitz OH, Hench KD, Barnes KM, Loriaux DL et al. Treatment of familial male precocious puberty with spironolactone and testolactone. New England Journal of Medicine. 1989;320(8):496-502.
Laue, L. ; Kenigsberg, D. ; Pescovitz, O. H. ; Hench, K. D. ; Barnes, K. M. ; Loriaux, Donald (Lynn) ; Cutler, G. B. / Treatment of familial male precocious puberty with spironolactone and testolactone. In: New England Journal of Medicine. 1989 ; Vol. 320, No. 8. pp. 496-502.
@article{67225fdd6def44a6b4e63e9ac7af9cbd,
title = "Treatment of familial male precocious puberty with spironolactone and testolactone",
abstract = "Because the pubertal growth spurt in boys appears to be mediated by both androgens and estrogens, we hypothesized that blockade of both androgen action and estrogen synthesis would normalize the growth of boys with familial male precocious puberty. To test this hypothesis, we studied nine boys (age range, 3.3 to 7.7 years) during treatment with an antiandrogen (spironolactone) or an inhibitor of androgen-to-estrogen conversion (testolactone), followed by treatment with both agents. After six months of observation without treatment, the first four boys received spironolactone for six months, followed by spironolactone and testolactone. The next five boys received testolactone for six moths, followed by spironolactone and testolactone. Neither spironolactone nor testolactone, given alone, was satisfactorily as a treatment for this condition. However, a combination of spironolactone and testolactone, given for at least six months, restored both the growth rate and the rate of bone maturation to normal prepubertal levels and controlled acne, spontaneous erections, and aggressive behavior. The combined therapy was associated with a significantly lower growth rate than testolactone alone (P <0.05) and a significantly lower rate of bone maturation than spironolactone alone (P <0.05). No important adverse effects were observed during combined treatment. Six of the nine boys continued to receive the combined therapy for an additional 12 months and maintained normal prepubertal rates of growth and bone maturation. The mean predicted height (± SEM) increased progressively during the combined treatment although the difference between the pretreatment and post-treatment protections was not significant (169.5 ± 2.8 at the end of treatment vs. 166.2 ± 4.5 cm before treatment; P = 0.29). We conclude that blockade of both androgen action estrogen synthesis with the combination of spironolactone and testolactone is an effective short-term treatment for familial male precocious puberty. Further study will be required, however, to assess the long-term outcome in boys who receive this treatment.",
author = "L. Laue and D. Kenigsberg and Pescovitz, {O. H.} and Hench, {K. D.} and Barnes, {K. M.} and Loriaux, {Donald (Lynn)} and Cutler, {G. B.}",
year = "1989",
language = "English (US)",
volume = "320",
pages = "496--502",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "8",

}

TY - JOUR

T1 - Treatment of familial male precocious puberty with spironolactone and testolactone

AU - Laue, L.

AU - Kenigsberg, D.

AU - Pescovitz, O. H.

AU - Hench, K. D.

AU - Barnes, K. M.

AU - Loriaux, Donald (Lynn)

AU - Cutler, G. B.

PY - 1989

Y1 - 1989

N2 - Because the pubertal growth spurt in boys appears to be mediated by both androgens and estrogens, we hypothesized that blockade of both androgen action and estrogen synthesis would normalize the growth of boys with familial male precocious puberty. To test this hypothesis, we studied nine boys (age range, 3.3 to 7.7 years) during treatment with an antiandrogen (spironolactone) or an inhibitor of androgen-to-estrogen conversion (testolactone), followed by treatment with both agents. After six months of observation without treatment, the first four boys received spironolactone for six months, followed by spironolactone and testolactone. The next five boys received testolactone for six moths, followed by spironolactone and testolactone. Neither spironolactone nor testolactone, given alone, was satisfactorily as a treatment for this condition. However, a combination of spironolactone and testolactone, given for at least six months, restored both the growth rate and the rate of bone maturation to normal prepubertal levels and controlled acne, spontaneous erections, and aggressive behavior. The combined therapy was associated with a significantly lower growth rate than testolactone alone (P <0.05) and a significantly lower rate of bone maturation than spironolactone alone (P <0.05). No important adverse effects were observed during combined treatment. Six of the nine boys continued to receive the combined therapy for an additional 12 months and maintained normal prepubertal rates of growth and bone maturation. The mean predicted height (± SEM) increased progressively during the combined treatment although the difference between the pretreatment and post-treatment protections was not significant (169.5 ± 2.8 at the end of treatment vs. 166.2 ± 4.5 cm before treatment; P = 0.29). We conclude that blockade of both androgen action estrogen synthesis with the combination of spironolactone and testolactone is an effective short-term treatment for familial male precocious puberty. Further study will be required, however, to assess the long-term outcome in boys who receive this treatment.

AB - Because the pubertal growth spurt in boys appears to be mediated by both androgens and estrogens, we hypothesized that blockade of both androgen action and estrogen synthesis would normalize the growth of boys with familial male precocious puberty. To test this hypothesis, we studied nine boys (age range, 3.3 to 7.7 years) during treatment with an antiandrogen (spironolactone) or an inhibitor of androgen-to-estrogen conversion (testolactone), followed by treatment with both agents. After six months of observation without treatment, the first four boys received spironolactone for six months, followed by spironolactone and testolactone. The next five boys received testolactone for six moths, followed by spironolactone and testolactone. Neither spironolactone nor testolactone, given alone, was satisfactorily as a treatment for this condition. However, a combination of spironolactone and testolactone, given for at least six months, restored both the growth rate and the rate of bone maturation to normal prepubertal levels and controlled acne, spontaneous erections, and aggressive behavior. The combined therapy was associated with a significantly lower growth rate than testolactone alone (P <0.05) and a significantly lower rate of bone maturation than spironolactone alone (P <0.05). No important adverse effects were observed during combined treatment. Six of the nine boys continued to receive the combined therapy for an additional 12 months and maintained normal prepubertal rates of growth and bone maturation. The mean predicted height (± SEM) increased progressively during the combined treatment although the difference between the pretreatment and post-treatment protections was not significant (169.5 ± 2.8 at the end of treatment vs. 166.2 ± 4.5 cm before treatment; P = 0.29). We conclude that blockade of both androgen action estrogen synthesis with the combination of spironolactone and testolactone is an effective short-term treatment for familial male precocious puberty. Further study will be required, however, to assess the long-term outcome in boys who receive this treatment.

UR - http://www.scopus.com/inward/record.url?scp=0024519195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024519195&partnerID=8YFLogxK

M3 - Article

C2 - 2492636

AN - SCOPUS:0024519195

VL - 320

SP - 496

EP - 502

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 8

ER -